Comparison · longevity

NAD+ vs NMN

NAD+ is delivered parenterally (IV or subcutaneous) to elevate intracellular NAD+ directly. NMN is an oral precursor that the body converts toward NAD+. Parenteral NAD+ produces higher and more predictable systemic exposure; NMN is convenient but has a less consistent evidence base.

Reviewed by Dr. Laura PurdyMay 29, 2026

Attribute

NAD+ (injectable/IV)

NMN (oral supplement)

Form

Injectable / IV

Oral capsule

Bioavailability

Direct systemic delivery

Variable; partially converted

Evidence base

Emerging clinical evidence

Emerging, less consistent

Cadence

Series under provider review

Daily supplementation

Regulatory status

Compounded clinical use

FDA recently classified NMN as not a dietary supplement

Pathway

NAD+ optimization

Not offered by oMeds

Choose NAD+ (injectable/IV)

Injectable or IV NAD+ is appropriate when direct systemic delivery and a provider-reviewed cadence are clinically indicated.

Explore pathway

Choose NMN (oral supplement)

Oral NMN is a consumer supplement category and is not part of the oMeds NAD+ pathway.

Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.

Frequently asked

Is NMN as effective as NAD+?

Current evidence suggests parenteral NAD+ produces more predictable elevation in NAD+ levels.

Why is NMN regulated differently?

In 2022 the FDA determined NMN does not meet the dietary-supplement definition; status continues to evolve.

Next step

Take the optimization assessment.

The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.

Begin assessment